AU2002241565A1 - Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders - Google Patents

Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders

Info

Publication number
AU2002241565A1
AU2002241565A1 AU2002241565A AU2002241565A AU2002241565A1 AU 2002241565 A1 AU2002241565 A1 AU 2002241565A1 AU 2002241565 A AU2002241565 A AU 2002241565A AU 2002241565 A AU2002241565 A AU 2002241565A AU 2002241565 A1 AU2002241565 A1 AU 2002241565A1
Authority
AU
Australia
Prior art keywords
treatment
amino acid
receptor antagonist
neurological disorders
acid receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002241565A
Inventor
Kirk Willis Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2002241565A1 publication Critical patent/AU2002241565A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002241565A 2001-01-05 2001-12-20 Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders Abandoned AU2002241565A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25992301P 2001-01-05 2001-01-05
US60/259,923 2001-01-05
PCT/US2001/045863 WO2002053139A2 (en) 2001-01-05 2001-12-20 Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders

Publications (1)

Publication Number Publication Date
AU2002241565A1 true AU2002241565A1 (en) 2002-07-16

Family

ID=22987001

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002241565A Abandoned AU2002241565A1 (en) 2001-01-05 2001-12-20 Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders

Country Status (2)

Country Link
AU (1) AU2002241565A1 (en)
WO (1) WO2002053139A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101825972B1 (en) 2010-10-15 2018-02-06 콘테라 파르마 에이피에스 Combinations of serotonin receptor agonists for treatment of movement disorders
EP2838517B1 (en) 2012-04-18 2017-10-18 Contera Pharma APS Orally available pharmaceutical formulation suitable for improved management of movement disorders
CN109689036A (en) 2016-07-11 2019-04-26 康特拉医药公司 For treating morning akinetic pulse delivery system

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521196A (en) * 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
TR199902449T2 (en) * 1997-04-07 2000-07-21 Eli Lilly And Company Pharmacologically active substances.
NZ515616A (en) * 1999-07-06 2004-05-28 Lilly Co Eli Selective iGluR5 receptor antagonists for the treatment of migraine

Also Published As

Publication number Publication date
WO2002053139A8 (en) 2003-11-13
WO2002053139A2 (en) 2002-07-11
WO2002053139A3 (en) 2002-08-22

Similar Documents

Publication Publication Date Title
AU2003286611A1 (en) Cytomodulating peptides and methods for treating neurological disorders
AU2003287045A1 (en) Cytokine antagonists for neurological and neuropsychiatric disorders
AU2003239489A1 (en) Method of treating dyslipidemic disorders
EP1471909A4 (en) Pharmaceutical composition and method for treating disorders of the central nervous system
AU2003249983A1 (en) Piperidines useful for the treatment of central nervous system disorders
AU2002356525A1 (en) Substituted amines for the treatment of neurological disorders
AU2003296341A8 (en) System and method for treating Parkinson's Disease and other movement disorders
IL157770A0 (en) Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
EP1446111A4 (en) Materials and methods for treatment of neurological disorders involving overactivation of glutamatergic ionotropic receptors
PL373835A1 (en) Use of cd23 antagonists for the treatment of neoplastic disorders
IL162475A0 (en) Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists
AU2002362115A1 (en) Composition and methods for treatment of neurological disorders
AU2002241565A1 (en) Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders
AU2001225664A1 (en) 5-ht3 receptor antagonists for treatment of disorders involving airway constriction
WO2000006082A3 (en) Treatment of anxiety disorders
NZ526625A (en) Method for preventing and treating visceral pain and gastrointestinal disorders
AU2002339673A1 (en) Agonists and antagonists of ryzn for the treatment of metabolic disorders
PT1368032E (en) Excitatory amino acid receptor antagonists
AU2003297259A1 (en) Methods and compositions for treating neurological disorders
AU2002227020A1 (en) Pyrrolidinylmethyl- and piperidinyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
AU2002346000A1 (en) Identification and characterization of multiple splice variants of the mu opioid receptor gene
IL156138A0 (en) Excitatory amino acid receptor antagonists
AU2001298029A1 (en) Derivatives of the (3s, 4ar, 6s, 8ar) 6-phenylamino-1, 2, 3, 4, 4a, 5, 6, 7, 8, 8a-decahydro isoquinoline-3-carboxylic acid as excitatory amino acid receptor antagonists for the treatment of neurological disorders and neurodegenerative diseases
AU2003250685A1 (en) Methods of identifying selective beta-1-adrenergic receptor antagonists
AU2002330073A1 (en) Materials and methods for treatment of neurological disorders involving overactivation of glutamatergic ionotropic receptors

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase